June is Myasthenia Gravis Awareness Month!
Did you know that patients with seronegative myasthenia gravis (snMG) face unique and often greater challenges than those with other forms of MG?
An April 2025 research study shows:
• snMG patients experience longer diagnostic delays and earlier symptom onset
• Only 15.9% achieve complete remission (compared to 27.8% of AChR-ab+ MG patients)
• They report more severe symptoms, higher fatigue, and greater impact on daily life and employment
The link to the research paper is in the comments.
Clinakos Inc. offers AI-powered, patient-centric Integrated Patient Data™ capabilities that enable insights and research in Myasthenia Gravis that include:
Real-world data on disease progression, integrating lab markers and validated quality of life measures like MG-ADL and QMG, to track patient status over time.
Comprehensive visibility into all healthcare providers involved—including neurologists, ophthalmologists, endocrinologists, and other specialists.
Detailed analysis of steroid burden, helping to monitor long-term treatment impact and optimize therapy plans.
Actionable insights into treatment patterns, supporting better clinical decisions and improved patient outcomes.
We are passionate and committed to advancing patient-centered research and supporting the MG community with data-driven insights and innovation.
To know more, reach out to us [https://lnkd.in/gp3gUmXc]
Follow us at Clinakos Inc..
